The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Also Read: Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall Omvoh works to reduce inflammation within ...
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...